No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.
OBJECTIVE
This study investigated whether the brain-derived neurotrophic factor (BDNF) gene Val66Met single-nucleotide polymorphism (SNP) is associated with antipsychotic-induced tardive dyskinesia (TD) in schizophrenia.


METHODS
Genotyping was performed for the BDNF gene Val66Met SNP in Korean schizophrenic patients with (n=83) and without TD (n=126) who were matched for antipsychotic drug exposure and other relevant variables.


RESULTS
The frequencies of genotypes (chi2=2.37, p=0.306) and alleles (chi2=0.03, p=0.867) did not differ significantly between these two groups.


CONCLUSIONS
These findings suggest that the BDNF polymorphism does not play a major role in the susceptibility to TD in schizophrenic patients.
Kang
Seung-Gul
SG
Department of Psychiatry, Korea University College of Medicine, and Kangbuk Samsung Hospital, Seoul, South Korea.
Choi
Jung-Eun
JE
An
Hyonggin
H
Lim
Se-Won
SW
Lee
Heon-Jeong
HJ
Han
Changsu
C
Kim
Yong-Ku
YK
Kim
Seung-Hyun
SH
Cho
Sung Nam
SN
Lee
Min-Soo
MS
Joe
Sook-Haeng
SH
Jung
In-Kwa
IK
Kim
Leen
L
D000328:Adult; D000483:Alleles; D019943:Amino Acid Substitution; D014150:Antipsychotic Agents / Q000009:adverse effects; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics*; D004409:Dyskinesia, Drug-Induced / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000502:physiology; D011110:Polymorphism, Genetic / Q000235:genetics*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy / Q000235:genetics*
D014150:Antipsychotic Agents; D019208:Brain-Derived Neurotrophic Factor